ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1050

Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care

Isabella Hartel1, Jay Patel1, David Gazeley2, Drake Johnson1, Justin Levinson1, Carmen Campbell1, Britney Youngchild3, Shelby Gomez3, Amannda Weber4, Jessica Michaud5, Laura Dickmann6, Sancia Ferguson7, Betty Chewning8, Christie Bartels9 and Shivani Garg10, 1University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 2Medical College of Wisconsin, Milwaukee, WI, 3University of Wisconsin, School of Pharmacy, Madison, WI, 4University of Wisconsin (UW), UW Health, Madison, WI, 5Medical College of Wisconsin, Milwaukee, Madison, WI, 6Medical College of Wisconsin, Milwaukee, Milwaukee, 7University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, 8University of Wisconsin, School of Pharmacy, Madison, 9University of Wisconsin School of Medicine and Public Health, Madison, WI, 10University of Madison, School of Medicine and Public Health, Madison, WI

Meeting: ACR Convergence 2025

Keywords: Decision analysis, Health Services Research, Qualitative Research, quality of care, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1038–1054) Health Services Research Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Hydroxychloroquine (HCQ) is a key therapy for lupus (or SLE). Yet, challenged to weigh benefits vs. harms, ~80% of patients self-discontinue HCQ. Shared decision-making (SDM) tools, like HCQ-SAFE© (Garg, 2023), can support patients and clinicians in complex treatment decisions. In a clinical trial, HCQ-SAFE SDM intervention (Fig. 1A) was used by 12 clinicians during 200 visits in 8 clinics of 2 health systems. Still adoption of SDM tools can be challenging in non-research settings, particularly busy clinics and low-resource settings. We aimed to: 1) examine implementation outcome metrics mapped to the RE-AIM framework for using the HCQ-SAFE SDM intervention; 2) develop strategies based on clinician experiences using the Normalization Process Theory (NPT) to revise HCQ-SAFE implementation workflow for easier integration in clinics.

Methods: The HCQ-SAFE SDM intervention (Fig. 1A) was implemented in 200 unique visits by 6 MDs, 3 PharmDs, and 3 RNs (NCT05922722). Clinicians completed a questionnaire to report intervention details (version, topics, language), time, and rated feasibility & likelihood to use on a 1-9 Likert scale (9=best). Clinicians also participated in a cognitive interview to share experiences, barriers, & facilitators to HCQ-SAFE use. Quantitative data from 200 questionnaires estimated RE-AIM implementation metrics. Reach: % eligible visits completing HCQ-SAFE. Effectiveness: change in decisional conflict scores (overall/by role). Adoption: % clinicians completing intervention. Implementation: Fidelity (% visits covering ≥1 benefit/harm, language) & Feasibility (median score ≥7, time ≤5 min).

Maintenance: monthly completion rate & Net Promoter Score (NPS ≥80%, motivators – detractors). Qualitative data from interviews were analyzed using a coding scheme informed by 4 NPT domains to identify strategies to refine workflows for easier integration of HCQ-SAFE in clinics.

Results: In 200 visits, MDs (50%), PharmDs (28%), and RNs (22%) completed the HCQ-SAFE intervention (Table 1). Data analysis showed excellent completion rates (100%) across MDs, PharmDs, RNs, with equally effective resolution of decisional conflicts regardless of clinician role (98% PharmD/RN vs. 99% MD; Table 1). Adoption was slightly lower among MDs (75%) vs. PharmDs/RNs (100%). HCQ-SAFE was rated highly feasible (median score 9, median time 5 mins) and received 100% NPS, indicating strong clinician willingness for continued use. Content analysis of clinician experiences using NPT yielded 6 strategies for HCQ-SAFE implementation (Table 2; Fig. 1B). Key recommendations included: tailoring training by role, simplifying eligibility to include all SLE patients, using PharmDs/RNs to lead reviews. Clinicians preferred this equally effective staff-led model for easier integration and facilitate team-based care. The revised clinical workflow (Fig. 1B) gained unanimous endorsement from participating clinicians.

Conclusion: The impact of this study is 2-fold. First, it establishes HCQ-SAFE is a highly feasible and effective SDM intervention for clinical use. Second, it delivers an end-user-informed practical workflow to ensure sustainable integration in clinics to promote medication adherence via SDM.

Supporting image 1Table 1. A. Key Visits Characteristics; B. Implementation Outcome Metrics Mapped to RE-AIM

Supporting image 2Table 2. Qualitative Analysis of Clinician Interviews Informed by Normalization Process Theory Domains to Deliver Strategies to Develop Practical Workflow for HCQ-SAFE Integration in Clinics

Supporting image 3Figure 1A. Swim Lane diagram showing the study workflow used to implement the HCQ-SAFE shared decision-making intervention across 200 unique patient visits in 8 clinics of 2 health systems; Figure 1B. An end-user-informed practical workflow for routine use of HCQ-SAFE shared decision-making intervention in clinics


Disclosures: I. Hartel: None; J. Patel: None; D. Gazeley: None; D. Johnson: None; J. Levinson: None; C. Campbell: None; B. Youngchild: None; S. Gomez: None; A. Weber: None; J. Michaud: None; L. Dickmann: None; S. Ferguson: None; B. Chewning: None; C. Bartels: None; S. Garg: None.

To cite this abstract in AMA style:

Hartel I, Patel J, Gazeley D, Johnson D, Levinson J, Campbell C, Youngchild B, Gomez S, Weber A, Michaud J, Dickmann L, Ferguson S, Chewning B, Bartels C, Garg S. Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/bridging-the-gap-a-mixed-methods-study-to-enhance-integration-of-hcq-safe-a-shared-decision-making-tool-for-hydroxychloroquine-use-in-routine-lupus-care/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bridging-the-gap-a-mixed-methods-study-to-enhance-integration-of-hcq-safe-a-shared-decision-making-tool-for-hydroxychloroquine-use-in-routine-lupus-care/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology